Asset Details
Do you wish to reserve the book?
Cryptococcal therapies and drug targets: the old, the new and the promising
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cryptococcal therapies and drug targets: the old, the new and the promising
Do you wish to request the book?
Cryptococcal therapies and drug targets: the old, the new and the promising
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cryptococcal therapies and drug targets: the old, the new and the promising
2016
Overview
Summary Half a century after the introduction of Amphotericin B the management of cryptococcosis remains unsatisfactory. The disease, caused primarily by the two fungal species Cryptococcus neoformans and Cryptococcus gattii, remains responsible for considerable morbidity and mortality despite standard medical care. Current therapeutic options are limited to Amphotericin B, azoles and 5‐flucytosine. However, this organism has numerous well‐characterized virulence mechanisms that are amenable to pharmacological interference and are thus potential therapeutic targets. Here, we discuss existing approved antifungal drugs, resistance mechanisms to these drugs and non‐standard antifungal drugs that have potential in treatment of cryptococcosis, including immunomodulatory strategies that synergize with antifungal drugs, such as cytokine administration or monoclonal antibodies. Finally, we summarize attempts to target well‐described virulence factors of Cryptococcus, the capsule or fungal melanin. This review emphasizes the pressing need for new therapeutic alternatives for cryptococcosis.
Publisher
John Wiley & Sons, Inc
Subject
Antifungal Agents - pharmacology
/ Cryptococcosis - drug therapy
/ Cryptococcosis - microbiology
/ Cryptococcus gattii - drug effects
/ Cryptococcus gattii - pathogenicity
/ Cryptococcus neoformans - pathogenicity
/ Drug Resistance, Fungal - drug effects
/ Drugs
/ Humans
/ Immunologic Factors - pharmacology
/ Molecular Targeted Therapy - methods
/ Nose
